SAINT LAURENT, Quebec, May 12, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V: IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a second feasibility agreement (the “SFA”) with ATAI Life Sciences AG (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications…


Previous articleHenrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets and Sacraments’
Next articleExploring Oregon’s Measure 110 and The Future of Drug Policy Reform